Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival ...

Researchers conducted a multicentre, non-interventional cohort study involving 114 adult patients (58.7% men) with locally advanced, unresectable, stage III NSCLC initiated on durvalumab following ...

Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation Eligible ...

Durvalumab significantly improves overall survival for patients with unresectable stage III non–small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that ...

Prevalence of Genomic Alterations in EGFR, KRAS, NRAS, and BRAF Among Early-Stage Nonsquamous Non–Small Cell Lung Cancer in Brazil Among 273 patients, cCRT and sCRT were administered with equal ...

The CONVERGE study evaluates NBTXR3's efficacy in stage III unresectable NSCLC with standard chemoradiation and durvalumab. NBTXR3, a hafnium oxide nanoparticle, is activated by radiotherapy to induce ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination with other oncology drugs. Announcing the data at the American Society of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating ...

(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) — Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and ...